Related Experiment Video

Updated: Jun 17, 2026

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1
07:59

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1

Published on: December 5, 2020

Targeting CCL11 in the treatment of ovarian cancer

Brian M Nolen1, Anna E Lokshin

  • 1University of Pittsburgh, Cancer Institute, Hillman Cancer Center, Suite 1.19d, 5117 Centre Avenue, Pittsburgh, PA 15213, USA.

Expert Opinion on Therapeutic Targets
|January 9, 2010
PubMed
Abstract

Insights

The chemokine CCL11 (also known as eotaxin) is involved in ovarian cancer development. Targeting CCL11 and its receptors offers a promising new treatment strategy for ovarian cancer.

Area of Science:

  • Oncology
  • Immunology
  • Inflammation Biology

Background:

  • The chemokine network, a system of inflammatory mediators, is increasingly linked to human cancer development.
  • CCL11, an eosinophil chemoattractant, has been identified as a key player in the progression of ovarian cancer.

Purpose of the Study:

  • This review examines the role of CCL11 in ovarian cancer.
  • It discusses CCL11 as a potential therapeutic target for ovarian cancer treatment.

Main Methods:

  • A review of published literature focusing on the physiological functions of CCL11.
  • Analysis of CCL11's tumor-promoting effects and its role within the ovarian cancer inflammatory microenvironment.
  • Evaluation of current therapeutic strategies targeting CCL11 and its receptors, with emphasis on recent findings (last 10 years).

Main Results:

  • The chemokine network plays a significant role in various malignancies.
  • CCL11 contributes to ovarian tumor development through specific actions and by influencing the tumor's inflammatory environment.
  • These unique characteristics make CCL11 an attractive target for therapeutic intervention in ovarian cancer.

Conclusions:

  • Targeting CCL11 and its receptors presents a novel therapeutic approach for ovarian cancer.
  • Monoclonal antibodies and small-molecule inhibitors are potential treatment modalities.

More Related Videos

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

In vitro Enrichment of Ovarian Cancer Tumor-initiating Cells11:37

In vitro Enrichment of Ovarian Cancer Tumor-initiating Cells

Published on: February 18, 2015

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.